10x Genomics Won a $4.8M Patent Case. That's Why the Stock Fell Anyway

On Aug. 28, 10x Genomics won a patent jury verdict against Parse Biosciences, a Qiagen-owned rival in single-cell analysis. Its stock slipped more than 5% anyway, right as the news hit a stock trading near a 52-week high. A court victory that knocks a stock down looks like a contradiction, and it's worth resolving, because the answer tells you what TXG now actually trades on.

The first reason the verdict couldn't lift the stock is size. The Delaware jury awarded 10x over $4.8 million in damages — about 0.06% of the company's roughly $8 billion market value. Even the 14% royalty the award implies, on Parse's infringing whole-transcriptome kits, is a rounding error next to 10x's roughly $620 million in annual revenue. The defendant's entire business — the single-cell unit Qiagen bought for $225 million, expected to contribute about $40 million a year — is materially smaller than 10x's. A check that size is a legal win, not a re-rating.

It was also a thinner win than the headline suggested. Nine days earlier, on Aug. 19, the Federal Circuit upheld rulings invalidating 10x's own patents asserted against Parse; this verdict instead rests on three patents 10x obtained by acquiring Scale Biosciences last August, which held an exclusive license from Roche. The outcome with any real value — a permanent U.S. injunction that would force a competitor to stop selling — is still pending post-trial motions and, almost certainly, appeal. Courts win; appeals win back.

But the deeper reason the market shrugged is that it was never pricing Parse in the first place. 10x has re-rated violently in 2026. The stock began the year near $16, traded as low as $11.16 over the past 12 months, and now sits around $61 — up roughly 276% year to date against a roughly 12% gain for the S&P 500, with most of the run-up already banked before the verdict landed. Investors re-rated this company on its own operating story, and a small legal win at the top of that move reads as sell-the-news, not as proof that the thesis broke.

What the market is paying up for is real, but incomplete. The business genuinely looks healthier than it did two years ago. Trailing free cash flow is about $121 million a year, the balance sheet carries essentially no net debt against $552 million in cash and marketable securities, and gross margin has climbed to roughly 70% — about 74% in the latest quarter. This is not the cash-burning company that fell from the hundreds to the teens. The 12-month story behind the re-rating is the Atera spatial platform, launched in April: management calls customer response "extraordinary," says booked orders already exceed the 40-unit 2026 shipment target — most units land in Q4 — and estimates each instrument generates $1.5 million to $3 million in recurring consumables annually, roughly double the capacity of the prior-generation system.

Here is where the honesty has to come in, because the cheapness is gone. The underlying topline is not growing like a story that belongs at these multiples. Full-year 2026 revenue is guided to $610–$630 million — roughly 2% to 5% growth after stripping out one-time patent-settlement money that flattered 2025's reported results. In Q2, reported revenue fell 12.6% year over year (up 3% excluding settlements), instrument sales dropped 47% as customers waited on Atera, and China revenue fell about 35%. The company still reports GAAP losses — a $17.9 million net loss in Q2 — and part of the positive cash flow traces to 2025 litigation settlements, one-time money rather than the recurring business.

Do the multiple math and the setup has clearly changed. At about $8 billion, TXG trades near 13 times trailing sales and roughly 65 times trailing free cash flow, for a business guiding to mid-single-digit growth. Even the aggregate analyst signal — a Hold, via AInvest — has not fully chased the tape. This is no longer the "market still pricing the old story while the operating setup gets cleaner" entry that was available when the stock traded in the low teens. The expectations reset happened. What's left at $61 is a priced bet that the good news keeps compounding.

Which is why I'd anchor to the cash-flow path, not the courtroom. Over the next 12 months the case rests on a handful of things you can actually check: whether the 40 Atera units ship on schedule and the guided Q4 step-up in revenue appears (a modest Q3 decline is in guidance as customers pause purchases of older instruments); whether placements convert into that $1.5–$3 million-a-year consumable pull-through; whether China stops sliding; and whether free cash flow holds as the launch absorbs spending. The thesis breaks if Atera slips — order-to-shipment delays or a soft Q4 — or if single-cell consumable growth stalls against a now better-financed rival, or if the cash flow reverses.

I can be wrong again, but not about the weight of this verdict. A $4.8 million award against an $8 billion company is a headline, not a cash-flow event. If you're deciding on TXG, decide on the Atera ramp and the free cash flow. The court is not the story.